Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 6/20 | 0.53 |
| ▸ | DRD2 | P14416 | 5/20 | 0.53 |
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4873768 | 0.91 | SOAT1 (0.55) | SOAT1MEN1MAPTKMT2ADRD4 | |
| SCHEMBL4878061 | 0.89 | SOAT1 (0.58) | SOAT1MEN1MAPTKMT2ADRD4 | |
| SCHEMBL5476169 | 0.88 | SOAT1 (0.55) | SOAT1MEN1MAPTKMT2ADRD4 | |
| SCHEMBL4878235 | 0.87 | SOAT1 (0.52) | SOAT1MEN1MAPTKMT2ADRD4 | |
| SCHEMBL14520340 | 0.85 | SOAT1 (0.55) | SOAT1MEN1MAPTKMT2ADRD4 | |
| SCHEMBL4880752 | 0.85 | SOAT1 (0.54) | SOAT1MAPTDRD4DRD2HTR1A | |
| SCHEMBL14520335 | 0.84 | SOAT1 (0.51) | SOAT1MEN1MAPTKMT2ADRD4 | |
| SCHEMBL14520338 | 0.83 | SOAT1 (0.53) | SOAT1DRD4DRD2HTR1AADRA1D | |
| SCHEMBL14520343 | 0.83 | SOAT1 (0.57) | SOAT1DRD4DRD2 | |
| SCHEMBL4876644 | 0.83 | SOAT1 (0.51) | SOAT1MAPTKMT2ADRD4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078120-A1 | Novel piperidine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1679069-A1 | NOVEL PIPERIDINE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078120-A1 | Novel piperidine derivative | LDLR, PRMT5, MSR1 | SOAT1 1040/4885MEN1 3200/4885MAPT 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.